Literature DB >> 6150753

Canine malignant hyperthermia susceptibility: erythrocytic defects--osmotic fragility, glucose-6-phosphate dehydrogenase deficiency and abnormal Ca2+ homeostasis.

P J O'Brien, G W Forsyth, D W Olexson, H S Thatte, P B Addis.   

Abstract

Two dogs were diagnosed as malignant hyperthermia susceptible based on increased susceptibility (P less than 0.001) of biopsied muscle to caffeine-induced contracture. Erythrocytes from malignant hyperthermia and normal dogs were then examined for an antioxidant system deficiency. Values for serum muscle enzymes, reticulocytes and corpuscular hemoglobin were mildly elevated. Osmotic fragility was increased: hemolysis occurred at a NaCl concentration 10 mM higher than for normal dogs (P less than 0.001). A 35% glucose-6-phosphate dehydrogenase deficiency (P less than 0.001) with a 40% compensatory increase (P less than 0.01) in 6-phosphogluconate dehydrogenase activity was found. The membrane Ca2+-activated ATPase activity was abnormal: 100% increased with a 40% decreased Arrhenius activation energy (P less than 0.005) and increased thermostability. A 40% increased intracellular accumulation of total Ca2+ occurred in response to in vitro energy depletion in erythrocytes from one malignant hyperthermia dog (P less than 0.01). The multifactorial pattern of inheritance and the broad spectrum of malignant hyperthermia susceptibility are proposed to result from an antioxidant system deficit unmasking or aggravating an intrinsic muscle membrane anomaly. An individual from a family with a history of malignant hyperthermia or unexplained anesthetic death should be considered malignant hyperthermia susceptible if erythrocyte osmotic fragility is abnormal and there is a mild, unexplained elevation in serum creatine kinase.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6150753      PMCID: PMC1236089     

Source DB:  PubMed          Journal:  Can J Comp Med        ISSN: 0008-4050


  55 in total

1.  Improved method for the determination of blood glutathione.

Authors:  E BEUTLER; O DURON; B M KELLY
Journal:  J Lab Clin Med       Date:  1963-05

2.  A microcolorimetric method for the determination of inorganic phosphorus.

Authors:  H H TAUSSKY; E SHORR
Journal:  J Biol Chem       Date:  1953-06       Impact factor: 5.157

3.  Preparation of Injectable Dantrolene for Emergency Treatment of Malignant Hyperthermia-like Syndromes.

Authors:  P J O'brien; G W Forsyth
Journal:  Can Vet J       Date:  1983-06       Impact factor: 1.008

Review 4.  Epidemiology and inheritance of malignant hyperthermia.

Authors:  W Kalow; B A Britt; F Y Chan
Journal:  Int Anesthesiol Clin       Date:  1979

5.  Mitochondrial calcium, erythrocyte fragility and porcine malignant hyperthermia.

Authors:  K S Cheah; A M Cheah
Journal:  FEBS Lett       Date:  1979-11-15       Impact factor: 4.124

Review 6.  Porcine stress syndromes.

Authors:  G Mitchell; J J Heffron
Journal:  Adv Food Res       Date:  1982

7.  An improvement of the Coomassie Blue dye binding method allowing an equal sensitivity to various proteins: application to cerebrospinal fluid.

Authors:  M Macart; L Gerbaut
Journal:  Clin Chim Acta       Date:  1982-06-16       Impact factor: 3.786

Review 8.  Lipid peroxidation in mitochondrial membrane.

Authors:  Y A Vladimirov; V I Olenev; T B Suslova; Z P Cheremisina
Journal:  Adv Lipid Res       Date:  1980

9.  Spectrum of susceptibility to malignant hyperthermia--diagnostic dilemma.

Authors:  T E Nelson; E H Flewellen; D F Gloyna
Journal:  Anesth Analg       Date:  1983-06       Impact factor: 5.108

10.  Electrodiagnostic analysis of peripheral neuropathy in dogs with diabetes mellitus.

Authors:  J E Steiss; A N Orsher; J M Bowen
Journal:  Am J Vet Res       Date:  1981-12       Impact factor: 1.156

View more
  10 in total

1.  Malignant hyperthermia in dogs.

Authors:  P J O'brien
Journal:  Can Vet J       Date:  1987-06       Impact factor: 1.008

2.  Author's reply.

Authors:  P H Cribb
Journal:  Can Vet J       Date:  1987-06       Impact factor: 1.008

Review 3.  Etiopathogenetic defect of malignant hyperthermia: hypersensitive calcium-release channel of skeletal muscle sarcoplasmic reticulum.

Authors:  P J O'Brien
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

Review 4.  Malignant hyperthermia susceptibility: biochemical basis for pathogenesis and diagnosis.

Authors:  P J O'Brien; A Klip; B A Britt; B I Kalow
Journal:  Can J Vet Res       Date:  1990-01       Impact factor: 1.310

Review 5.  Creatine kinase in the dog: a review.

Authors:  M Aktas; D Auguste; H P Lefebvre; P L Toutain; J P Braun
Journal:  Vet Res Commun       Date:  1993       Impact factor: 2.459

6.  Porcine malignant hyperthermia susceptibility: hypersensitive calcium-release mechanism of skeletal muscle sarcoplasmic reticulum.

Authors:  P J O'Brien
Journal:  Can J Vet Res       Date:  1986-07       Impact factor: 1.310

7.  Measurement of the cytotoxic effects of different strains of Mycoplasma equigenitalium on the equine uterine tube using a calmodulin assay.

Authors:  V M Bermúdez; R B Miller; S Rosendal; M A Fernando; W H Johnson; P J O'Brien
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

8.  Malignant hyperthermia susceptibility: cardiac histomorphometry of dogs and young and market-weight swine.

Authors:  P J O'Brien; T F Fletcher; A L Metz; H J Kurtz; B K Reed; W E Rempel; E G Clark; C F Louis
Journal:  Can J Vet Res       Date:  1987-01       Impact factor: 1.310

9.  Erythrocyte osmotic fragility testing and the prediction of canine malignant hyperthermia susceptibility.

Authors:  P H Cribb; E A Olfert; F B Reynolds
Journal:  Can Vet J       Date:  1986-12       Impact factor: 1.008

10.  Effects of Ureaplasma diversum on bovine oviductal explants: quantitative measurement using a calmodulin assay.

Authors:  B Smits; S Rosendal; H L Ruhnke; C Plante; P J O'Brien; R B Miller
Journal:  Can J Vet Res       Date:  1994-04       Impact factor: 1.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.